Literature DB >> 8665315

Xenograft growth and histodifferentiation of squamous cell carcinomas of the pharynx and larynx.

J Chen1, G E Milo, C F Shuler, D E Schuller.   

Abstract

The potential for growth in a xenogeneic host and the pattern of histodifferentiation was examined in 56 human squamous cell carcinomas of the pharynx and larynx transplanted to nude mice. Among these 56 transplanted tumors, 13 of 36 primary and 12 of 20 metastatic tumors were found to be tumorigenic in nude mice. Eleven of 24 pharyngeal and 14 of 32 laryngeal tumors grew in nude mice. The dynamics of transplanted tumor growth in the surrogate host took place independent of the tumor grade and site of tumor origin. Transplanted tumors exhibited a higher mitotic index compared with the original tumors. Each passage of a tumor line resulted in most of the xenograft tumors exhibiting an increased degree of differentiation without invasion of host tissues. No difference was observed between patients who engrafted tumors in the xenograft model and those who did not with respect to tumor biology or clinical findings, including survival.

Entities:  

Mesh:

Year:  1996        PMID: 8665315     DOI: 10.1016/s1079-2104(96)80415-x

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  7 in total

1.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 2.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

3.  Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Authors:  Hua Li; Sarah Wheeler; Yongseok Park; Zhenlin Ju; Sufi M Thomas; Michele Fichera; Ann M Egloff; Vivian W Lui; Umamaheswar Duvvuri; Julie E Bauman; Gordon B Mills; Jennifer R Grandis
Journal:  Mol Cancer Res       Date:  2015-12-18       Impact factor: 5.852

4.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.

Authors:  Stephen B Keysar; David P Astling; Ryan T Anderson; Brian W Vogler; Daniel W Bowles; J Jason Morton; Jeramiah J Paylor; Magdalena J Glogowska; Phuong N Le; Justin R Eagles-Soukup; Severine L Kako; Sarah M Takimoto; Daniel B Sehrt; Adrian Umpierrez; Morgan A Pittman; Sarah M Macfadden; Ryan M Helber; Scott Peterson; Diana F Hausman; Sherif Said; Ted H Leem; Julie A Goddard; John J Arcaroli; Wells A Messersmith; William A Robinson; Fred R Hirsch; Marileila Varella-Garcia; David Raben; Xiao-Jing Wang; John I Song; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Oncol       Date:  2013-04-04       Impact factor: 6.603

5.  Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

Authors:  Lorin Dodbiba; Jennifer Teichman; Andrew Fleet; Henry Thai; Maud H W Starmans; Roya Navab; Zhuo Chen; Hala Girgis; Lawson Eng; Osvaldo Espin-Garcia; Xiaowei Shen; Bizhan Bandarchi; Joerg Schwock; Ming-Sound Tsao; Hala El-Zimaity; Sandy D Der; Wei Xu; Robert G Bristow; Gail E Darling; Paul C Boutros; Laurie E Ailles; Geoffrey Liu
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

6.  Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts.

Authors:  Andrew P Stein; Sandeep Saha; Cheng Z Liu; Gregory K Hartig; Paul F Lambert; Randall J Kimple
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

7.  Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.

Authors:  Megan L Ludwig; Andrew C Birkeland; Rebecca Hoesli; Paul Swiecicki; Matthew E Spector; J Chad Brenner
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.